Mantle cell lymphoma

Common Name(s)

Mantle cell lymphoma

Mantle cell lymphoma (MCL) belongs to a group of diseases known as  non-HodgkinÕs lymphomas (NHL), which are cancers that affect the the lymphatic system (part of the immune system). MCL accounts for 6% of all non-Hodgkin lymphomas and is mostly found in males during their early 60s. Lymphocytes, which are white blood cells that make up the lymphatic system. There are two main types: B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Mantel cell lymphoma is a B-cell lymphoma that develops from cancerous B-cells within a region of the lymph node known as the mantle zone. Although mantle cell lymphomas are slow-growing cancers, at the time of diagnosis, they are usually widespread in the lymph nodes and require intensive treatment because they can become lethal within a short period of time.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Mantle cell lymphoma" for support, advocacy or research.

National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Mantle cell lymphoma" for support, advocacy or research.

National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Mantle cell lymphoma" returned 612 free, full-text research articles on human participants. First 3 results:

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
 

Author(s): H Saito, D Maruyama, A M Maeshima, S Makita, H Kitahara, K Miyamoto, S Fukuhara, W Munakata, T Suzuki, Y Kobayashi, H Taniguchi, K Tobinai

Journal:

 

Last Updated: 27 Oct 2015

Go To URL
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
 

Author(s): Baohua Sun, Bhavin Shah, Warren Fiskus, Jun Qi, Kimal Rajapakshe, Cristian Coarfa, Li Li, Santhana G T Devaraj, Sunil Sharma, Liang Zhang, Michael L Wang, Dyana T Saenz, Stephanie Krieger, James E Bradner, Kapil N Bhalla

Journal: Blood. 2015 Sep;126(13):1565-74.

 

Mantle cell lymphoma (MCL) cells exhibit increased B-cell receptor and nuclear factor (NF)-κB activities. The bromodomain and extra-terminal (BET) protein bromodomain 4 is essential for the transcriptional activity of NF-κB. Here, we demonstrate that treatment with the BET protein ...

Last Updated: 25 Sep 2015

Go To URL
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
 

Author(s): Sophie Bernard, Lauriane Goldwirt, Sandy Amorim, Pauline Brice, Josette Brière, Eric de Kerviler, Samia Mourah, Hélène Sauvageon, Catherine Thieblemont

Journal: Blood. 2015 Oct;126(14):1695-8.

 

The risk of central nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the course of the disease. However, prognosis in such cases remains extremely poor despite high-dose antimetabolite chemotherapy. Among novel drugs used to treat relapsing ...

Last Updated: 2 Oct 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Mantle cell lymphoma" returned 44 free, full-text review articles on human participants. First 3 results:

Mantle cell lymphoma-management in evolution.
 

Author(s): Saurabh Rajguru, Brad S Kahl

Journal: Chin Clin Oncol. 2015 Mar;4(1):8.

 

The management of mantle cell lymphoma (MCL) has been an area of rapid change in recent years. These changes have improved the prognosis for a disease that has had historically poor outcomes. There are several treatment options for the patient with newly diagnosed MCL, with younger, ...

Last Updated: 6 Apr 2015

Go To URL
Mantle cell lymphoma: evolving management strategies.
 

Author(s): Elias Campo, Simon Rule

Journal: Blood. 2015 Jan;125(1):48-55.

 

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma that generally affects older individuals and continues to have one of the worst outcomes of all the lymphomas. Over the last decade, there has been a widespread adoption of cytarabine-based therapy ...

Last Updated: 2 Jan 2015

Go To URL
Ibrutinib for the treatment of mantle cell lymphoma.
 

Author(s): Alex F Herrera, Eric D Jacobsen

Journal: Clin. Cancer Res.. 2014 Nov;20(21):5365-71.

 

Ibrutinib (PCI-32765)--a potent, covalent inhibitor of Bruton tyrosine kinase (BTK), an important kinase in the B-cell receptor signaling pathway--was recently approved by the FDA for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The drug was granted accelerated ...

Last Updated: 1 Nov 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
 

Status: Recruiting

Condition Summary: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma

 

Last Updated: 7 Dec 2015

Go to URL
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
 

Status: Recruiting

Condition Summary: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma

 

Last Updated: 14 Jan 2015

Go to URL
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
 

Status: Recruiting

Condition Summary: Stage I Mantle Cell Lymphoma; Stage II Contiguous Mantle Cell Lymphoma; Stage II Non-Contiguous Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma

 

Last Updated: 28 Oct 2015

Go to URL